Form 4: Zimmer Biomet CFO's RSU Vesting & Tax-Related Share Sale

Zimmer Biomet Holdings, Inc. CFO Suketu Upadhyay reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Summary

• Suketu Upadhyay, Executive VP and CFO of Zimmer Biomet Holdings, Inc. (ZBH), reported changes in beneficial ownership.
• On February 25, 2026, 6,364 shares of common stock were acquired through the vesting of restricted stock units (RSUs) at a price of $0.
• Concurrently, 2,832 shares of common stock were disposed of at a price of $99.51 to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions, Suketu Upadhyay directly beneficially owns 61,285 shares of common stock.
• One-third of the RSUs vested on February 25, 2026, with the remaining RSUs scheduled to vest one-half on February 25, 2027, and one-half on February 25, 2028.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It reports a routine, pre-scheduled executive compensation event (RSU vesting) and a standard tax-related share disposition, providing no new material information regarding the company's operational or financial performance.

Positives

• The vesting of 6,364 restricted stock units represents a component of executive compensation for Suketu Upadhyay, indicating continued alignment with company performance.

Negatives

• A disposition of 2,832 shares of common stock occurred, reducing the executive's direct ownership, although this was for tax withholding purposes.

Future Outlook

The remaining restricted stock units held by Suketu Upadhyay are scheduled to vest in two equal tranches on February 25, 2027, and February 25, 2028, indicating future compensation events.

Industry Context

StockSavvy.ai notes that the vesting of restricted stock units and subsequent tax-related share sales are standard practices in executive compensation across various industries, including medical technology. These transactions are typically pre-scheduled and do not usually reflect discretionary trading decisions by the executive.

Comparison to Industry Standards

• The structure of RSU vesting and tax withholding is a common compensation mechanism for executives in publicly traded companies, aligning with typical industry practices for long-term incentive plans.
• The reported transaction is consistent with standard executive compensation disclosures seen in peer companies within the medical device and healthcare sector.

Stakeholder Impact

• Shareholders: The impact is minimal as this is a routine executive compensation event and tax-related share sale, not indicative of a change in company fundamentals or executive sentiment beyond the pre-arranged compensation structure.

Next Steps

• Future vesting of remaining restricted stock units for Suketu Upadhyay on February 25, 2027.
• Future vesting of remaining restricted stock units for Suketu Upadhyay on February 25, 2028.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-scheduled vesting of restricted stock units and a subsequent tax-related share sale by a key executive. Such transactions are common and do not typically provide new fundamental information that would warrant a change in an investment thesis for Zimmer Biomet Holdings, Inc. Therefore, a 'hold' recommendation is appropriate as the filing does not alter the company's underlying value proposition or outlook.

Keywords

ZBH, Zimmer Biomet, Suketu Upadhyay, Form 4, Insider Transaction, RSU Vesting, Stock Compensation, CFO